AstraZeneca and Oxford University became the first vaccine makers to publish final stage COVID-19 vaccine trial results.
AstraZeneca and Oxford University on Tuesday became the first COVID-19 vaccine makers to publish their final-stage clinical trial vaccine data in a scientific journal.
This, as it cleared a key hurdle in the global race in order to produce effective and safe drugs for the coronavirus disease.
The said study, which was published in the Lancet medical journal, confirmed that the COVID-19 vaccine worked in an average of 70% of cases.
It came during a flurry of positive developments that had raised hopes the roll-out of COVID-19 vaccines could help start to restrain a coronavirus pandemic that had killed over 1.5 million people and stricken societies worldwide.
Oxford Vaccine Group director Andrew Pollard said that the publication showed that developers were sharing data “transparently”, adding that a range of COVID-19 vaccines would be needed.
READ ALSO: Deal With AstraZeneca May Be Deemed Void If Vaccine Fails To Get FDA Approval, Says DOH
In a press briefing, Pollard said that this couldn’t be a competition between developers, but this had to be a competition against the coronavirus instead.
Pollard also said that it’s incorporated into the trial with the agreement of regulators once researchers realized the measurement discrepancy.
“I think it is fair to say it needs more looking into to explain the intriguing result,” Pollard said.
AstraZeneca, meanwhile, said that it would be up to the regulators to decide dosing recommendations based on the vaccine data provided.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via official Facebook page and YouTube channel.
